Literature DB >> 12596760

Chronic kidney disease and the transplant recipient.

John S Gill1, Brian J G Pereira.   

Abstract

The recent Kidney Disease Outcomes Quality Initiative (K/DOQI) classification of chronic kidney disease (CKD) includes transplant recipients. Although there are important differences between kidney transplant recipients (KTRs) and patients with native kidney disease, the inclusion of KTRs along with other CKD patients is an important step to improve long-term outcomes among transplant recipients. In this article we discuss the applicability of the K/DOQI classification of CKD to transplant recipients and the importance of premature patient death with graft function as a cause of graft loss. The implementation of a comprehensive program of CKD care beginning prior to transplantation and continuing after graft failure is discussed as a strategy to improve patient outcomes and specific areas of concern for KTRs are highlighted.

Entities:  

Mesh:

Year:  2003        PMID: 12596760     DOI: 10.1159/000067871

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  3 in total

1.  Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Authors:  Andrew G Bostom; Myra A Carpenter; John W Kusek; Andrew S Levey; Lawrence Hunsicker; Marc A Pfeffer; Jacob Selhub; Paul F Jacques; Edward Cole; Lisa Gravens-Mueller; Andrew A House; Clifton Kew; Joyce L McKenney; Alvaro Pacheco-Silva; Todd Pesavento; John Pirsch; Stephen Smith; Scott Solomon; Matthew Weir
Journal:  Circulation       Date:  2011-04-11       Impact factor: 29.690

2.  Initial vascular access type in patients with a failed renal transplant.

Authors:  Micah R Chan; Bharvi Oza-Gajera; Kevin Chapla; Arjang X Djamali; Brenda L Muth; Jennifer Turk; Maureen Wakeen; Alexander S Yevzlin; Brad C Astor
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 8.237

3.  Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Authors:  Andrew G Bostom; Myra A Carpenter; Lawrence Hunsicker; Paul F Jacques; John W Kusek; Andrew S Levey; Joyce L McKenney; Renee Y Mercier; Marc A Pfeffer; Jacob Selhub
Journal:  Am J Kidney Dis       Date:  2008-11-20       Impact factor: 8.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.